Q3 saw 7% sales growth in NOK, led by Americas' strong recovery, while EMEA and APAC declined for the quarter but EMEA remains up year-to-date. EBIT margin normalized at 24%, with higher costs from new direct operations and increased R&D spend. Vascular and flow products drove growth, while imaging sales lagged.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.